In 2023,drug discovery develops steadily,with improvement of small molecule drugs discovery keeps pace with biological drugs in this year.The Center for Drug Evaluation and Research of U.S.Food and Drug Administration has totally approved 55 kinds of new drugs which have significantly promotion compared to 37 new drugs approval in 2022,including 38 kinds of new molecular entities,17 kinds of biological drugs,5 kinds of gene therapeutics and 2 cell therapeutics.The proportion of first-in-class drugs increased steadily,with 13 small molecule first-in-class drugs and 7 biological first-in-class drugs approved this year,mostly in the fields of cancer and rare diseases.Among them,a plurality of first-initiated small molecule drugs exhibits breakthrough significance,such as the first neurokinin 3(NK3)receptor antagonist fezolinetant,the first retinoic acid receptor(RIG-Ⅰ)agonist palovarotene,the first protein kinase B(AKT)inhibitor capivasertib,the first complement factor B inhibitor iptacopan,etc.The pioneering drug has huge academic and commercial value,and has become the target of the academic and industrial circles.However,first-in-class drugs not only need new targets,new mechanisms and new molecules,but also need to comprehensively verify the causality between new targets and diseases,study the correlation between new mechanisms and drug efficacy,and explore the balance between new molecules and drug-manufacturing properties.This article analyzed the research background,development process and therapeutic application of three first-initiated small molecule drugs in this year,expecting to provide more research ideas and methods for more first-in-class drugs.
first-in-class drugdrug discoverysmall molecule drug
万方数据
维普
